Credit Suisse’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Credit Suisse’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-32,156	Closed	-$3.14M	–	4755
2015 Q1	$3.14M	Buy	32,156 +6,382	+25%	+$676K	﹤0.01%	2036
2014 Q4	$2.39M	Buy	25,774 +12,112	+89%	+$956K	﹤0.01%	2398
2014 Q3	$940K	Sell	13,662 -4,759	-26%	-$341K	﹤0.01%	3112
2014 Q2	$1.93M	Sell	18,421 -5,978	-25%	-$509K	﹤0.01%	2748
2014 Q1	$2.02M	Buy	24,399 +7,726	+46%	+$714K	﹤0.01%	2496
2013 Q4	$1.08M	Buy	16,673 +8,871	+114%	+$527K	﹤0.01%	3212
2013 Q3	$495K	Sell	7,802 -21,654	-74%	-$1.07M	﹤0.01%	3504
2013 Q2	$1.24M	Buy	+29,456	New	+$1.34M	﹤0.01%	2633

Credit Suisse's GEVA Position: Q2 2015 in Review

Credit Suisse sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 32,156 shares — an estimated $3.14M sold.

Credit Suisse first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $3.14M in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

Credit Suisse reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
Credit Suisse sold 32,156 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $3.14M.
Credit Suisse first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
Credit Suisse's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $3.14M in Q1 2015.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Credit Suisse's 13F filing for Q2 2015, filed 13 Aug 2015.